Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Innate Pharma S.A. ADR (NQ: IPHA )

3.320 UNCHANGED
Streaming Delayed Price Updated: 3:52 PM EDT, Jun 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Innate Pharma S.A. ADR

< Previous 1 2 3 4 5 6 Next >
Innate Pharma to Participate in Upcoming Investor Conferences
From Innate Pharma SA
Via Business Wire
20 Stocks Moving in Tuesday's Pre-Market Session
Gainers Aptorum Group Limited (NASDAQ: APM) shares rose 94.4% to $3.15 in pre-market trading after gaining around 10% on Monday. The FDA recently granted Orphan Drug Designation... 
Via Benzinga
Number of Shares and Voting Rights of Innate Pharma as of January 1, 2022
From Innate Pharma S.A.
Via Business Wire
The Daily Biotech Pulse: Pfizer-BioNTech Partner For Shingles Vaccine, Annexon Huntington Disease Study Disappoints, Amneal Buys Neurology Assets
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Annexon Announces Mixed Phase 2 Data From Huntington Disease Trial Annexon,... 
Via Benzinga
Innate Pharma Obtains €28.7m in Non-Dilutive Financing in the Form of State Guaranteed Loans
From Innate Pharma SA
Via Business Wire
Innate Pharma to Participate in Upcoming Investor Conferences
From Innate Pharma SA
Via Business Wire
18 Stocks Moving in Monday's Pre-Market Session
Gainers Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) rose 41.6% to $3.13 in pre-market trading after gaining around 8% on Friday. Armstrong Flooring, Inc. (NYSE: AFI... 
Via Benzinga
Innate Pharma: First Patient Dosed in IPH6101/SAR443579 Phase 1/2 Clinical Trial in Various Blood Cancers
From Innate Pharma SA
Via Business Wire
Innate Pharma Says Chemo-Free Monalizumab Triplet Therapy Shows Preliminary Anti-Cancer Activity
Innate Pharma SA's (NASDAQ: IPHA) data from the Phase 2 expansion cohort (cohort 3) evaluating the monalizumab triplet combination shows preliminary activity and an... 
Via Benzinga
The Daily Biotech Pulse: Reata Plunges On Adcom Snub, AstraZeneca Antibody Cocktail Authorized For COVID-19 Prevention, NeuroSense IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus FDA Committee Votes Against Recommending Approval Of Kidney Disease Drug... 
Via Benzinga
Exposures COVID-19 Product Safety
Innate Pharma: Monalizumab Combined With Cetuximab and Durvalumab Demonstrates Anti-Tumor Activity in First-Line Recurrent or Metastatic Head and Neck Cancer at ESMO Immuno-Oncology 2021 Congress
From Innate Pharma S.A.
Via Business Wire
Innate Pharma to Present Monalizumab Data at ESMO Immuno-Oncology 2021 Congress
From Innate Pharma SA
Via Business Wire
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative... 
Via Benzinga
Exposures Product Safety
Innate Pharma to Participate in the Evercore ISI 4th Annual HealthConX Virtual Conference
From Innate Pharma SA
Via Business Wire
Innate Pharma Third Quarter 2021 Report
From Innate Pharma S.A.
Via Business Wire
Innate Pharma Announces Conference Call and Webcast for Q3 2021 Business Update
From Innate Pharma SA
Via Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Artelo Biosciences (NASDAQ:ARTL) stock moved upwards by 55.11% to $1.11 during Monday's pre-market session. The company's market cap stands at $27.1... 
Via Benzinga
Innate Pharma 2022 Financial Calendar
From Innate Pharma SA
Via Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Medpace Hldgs (NASDAQ:MEDP) shar... 
Via Benzinga
Number of Shares and Voting Rights of Innate Pharma as of October 1, 2021
From Innate Pharma
Via Business Wire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers OptimizeRx (NASDAQ:OPRX) stock increased by 12.12% to $84.05 during Thursday's pre-market session. The company's market cap stands at $1.4 billion.... 
Via Benzinga
18 Stocks Moving in Thursday's Pre-Market Session
Gainers Superior Drilling Products, Inc. (NYSE: SDPI) rose 58.7% to $1.73 in pre-market trading after jumping over 23% on Wednesday. The company, last month, reported Q2... 
Via Benzinga
50 Biggest Movers From Yesterday
Check out these big penny stock gainers and losers Losers Edesa Biotech, Inc. (NASDAQ: EDSA) shares dipped 29.9% to close at $8.36 on profit-taking after the stock... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Corvus Pharmaceuticals (NASDAQ:CRVS) stock moved upwards by 30.95% to $8.08 during Tuesday's regular session. As of 12:30 EST, this security is trading at a... 
Via Benzinga
32 Stocks Moving In Tuesday's Mid-Day Session
Gainers Helbiz, Inc. (NASDAQ: HLBZ) shares jumped 177.4% to $39.83. Helbiz Media, the media arm of Helbiz announced a deal with Amazon Italy, a unit of Amazon.com. ReWalk... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Viridian Therapeutics (NASDAQ:VRDN) shares rose 18.05% to $12.62 during Tuesday's pre-market session. The company's market cap stands at $120.9 million.... 
Via Benzinga
18 Stocks Moving in Tuesday's Pre-Market Session
Gainers ReWalk Robotics Ltd. (NASDAQ: RWLK) rose 37% to $1.78 in pre-market trading after declining around 4% on Monday. ReWalk Robotics, last month, reported Q2 sales of $1.44... 
Via Benzinga
48 Biggest Movers From Friday
Gainers Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) shares jumped 135.4% to settle at $5.32 on Friday. The stock possibly traded higher following favorable data results by... 
Via Benzinga
Global Radiotherapy Market Expected To Reach $7.3 Billion with a CAGR Of 4.2% By 2026
Via FinancialNewsMedia
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Corvus Pharmaceuticals (NASDAQ:CRVS 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.